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Abstract
Background: The majority of cancer patients experience dramatic weight loss, due to cachexia and consisting of 
skeletal muscle and fat tissue wasting. Cachexia is a negative prognostic factor, interferes with therapy and worsens the 
patients' quality of life by affecting muscle function. Mice bearing ectopically-implanted C26 colon carcinoma are 
widely used as an experimental model of cancer cachexia. As part of the search for novel clinical and basic research 
applications for this experimental model, we characterized novel cellular and molecular features of C26-bearing mice.
Methods: A fragment of C26 tumor was subcutaneously grafted in isogenic BALB/c mice. The mass growth and 
proliferation rate of the tumor were analyzed. Histological and cytofluorometric analyses were used to assess cell 
death, ploidy and differentiation of the tumor cells. The main features of skeletal muscle atrophy, which were 
highlighted by immunohistochemical and electron microscopy analyses, correlated with biochemical alterations. 
Muscle force and resistance to fatigue were measured and analyzed as major functional deficits of the cachectic 
musculature.
Results: We found that the C26 tumor, ectopically implanted in mice, is an undifferentiated carcinoma, which should 
be referred to as such and not as adenocarcinoma, a common misconception. The C26 tumor displays aneuploidy and 
histological features typical of transformed cells, incorporates BrdU and induces severe weight loss in the host, which is 
largely caused by muscle wasting. The latter appears to be due to proteasome-mediated protein degradation, which 
disrupts the sarcomeric structure and muscle fiber-extracellular matrix interactions. A pivotal functional deficit of 
cachectic muscle consists in increased fatigability, while the reported loss of tetanic force is not statistically significant 
following normalization for decreased muscle fiber size.
Conclusions: We conclude, on the basis of the definition of cachexia, that ectopically-implanted C26 carcinoma 
represents a well standardized experimental model for research on cancer cachexia. We wish to point out that 
scientists using the C26 model to study cancer and those using the same model to study cachexia may be unaware of 
each other's works because they use different keywords; we present strategies to eliminate this gap and discuss the 
benefits of such an exchange of knowledge.
Background
Cancer genome projects are providing complete land-
scapes of the mutations that exist in tumors, making it
essential to bridge the gap between high-throughput
sequencing information and the molecular mechanisms
underlying the natural history of cancer [1]. In this
regard, there is an unprecedented need for mammal
models of cancer: mice with naturally occurring onco-
genic mutations have provided important information
regarding cancer pathogenesis; genetically engineered
mice have emerged as essential tools for both mechanistic
studies and drug development in cancer research; trans-
plantation models (xenografts) have been useful in the
study of metastasis and for testing potential therapies.
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Mouse models of colon cancer have been extensively
revised by Taketo and Edelmann [2], as well as by Rosen-
berg and Tanaka [3].
Cancer cachexia is a muscle wasting syndrome that
a f f e c t s  m o s t  c a n c e r  p a t i e n t s  [ 4 ] .  C a c h e x i a  i s  a c k n o w l -
edged to be a serious complication in many chronic dis-
eases and is associated with a poor prognosis [5]. Indeed,
cachexia not only affects therapy and the patients' quality
of life, but is responsible for at least 20% of cancer deaths
[6]. The lack of an official definition of cachexia may have
led to its prevalence being underestimated, to misdiag-
noses and to conflicting data being reported [5]. A major
effort has recently been made to reach the following con-
sensus definition of cachexia: a metabolic syndrome asso-
ciated with underlying illness and characterized by loss of
muscle, with or without loss of fat mass, frequently asso-
ciated with anorexia, inflammation, insulin resistance
and increased muscle protein breakdown [7].
The genesis of the C26 colon carcinoma model
In 1975, during an effort to establish an animal colon
tumor model for biological and chemotherapy studies,
colon tumors were induced and transplanted in different
inbred mouse strains. Four tumors survived the first
transplant, which displayed a variety of histological and
malignancy features. These four tumors included the
colon tumor 26, described as an undifferentiated Grade
IV carcinoma that metastasizes above all in the lungs [8].
In 1981, the colon tumor 26 was further characterized in
vivo  by inoculation of serial cell doses into syngeneic
BALB/c mice. The C26 line was highly tumorigenic and
displayed a low tendency to metastasize; C26-inoculated
mice exhibited high mortality [9]. In 1990, C26-
implanted mice were reported to suffer extensive carcass
weight loss (40% of the control body weight), hypoglyce-
mia and hypercorticism in the presence of unchanged
food intake. C26 caused hepatic function disorders and
loss of adipose and skeletal muscle tissue, thus proving to
be an appropriate model for investigating the mecha-
nisms underlying cachexia [10]. Recently, we and others
have subcutaneously implanted a solid fragment of the
C26 tumor, as opposed to a cell suspension of C26 cells,
in the flank or dorsal region of mice [11-13]. It is note-
worthy that C26-induced cachexia varies according to the
inoculation site [14].
Use of the C26 model for cancer studies
The C26 model has been used over the last three decades
for research on the natural history of carcinomas and
antitumor therapy. These studies range from earlier
investigations exploiting C26 cells injected directly into
the spleen of syngeneic mice to study the efficacy of
MMP inhibitors [15], to a report showing that reduced
angiopoietin availability at the tumor site hampers
neoangiogenesis and thus limits tumor growth and
metastases [16]. Since liver and lung metastases are the
predominant cause of colorectal cancer-related mortality,
cancers of the gastrointestinal tract are widely used to
develop anti-tumor therapies. In this context, C26 cells
were injected in mice to investigate i) the potential of
CXCR3 antagonism to counteract the progression of can-
cer cells to target organs [17], ii) the antitumor effect of
liposomal formulation of glucocorticoids [18] and iii) the
effects of combined interstitial laser coagulation and dox-
orubicin treatment [19]. Mice either orthotopically or
ectopically implanted with C26 cells were used to study
the effects of several other anti-tumor agents [20,21].
Interestingly, two subclones have been isolated of C26
cells featuring differential sensitivity to 5-fluorouracil,
which may represent an important determinant of drug
sensitivity and treatment response [22]. While C26 cells
are initially responsive to the blockade of MAP kinase
pathways, they may become resistant to MAP kinase
inhibitors due to K-ras activation [23]. C26 cells have also
been used to demonstrate the antitumor effects of inter-
leukin-18, interleukin-27 and the chemokine CCL21/SLC
[24-26]. Further studies based on the C26 model were
aimed at developing novel karyotypic analysis approaches
to verify and track the origin and evolution of tumor cell
lines [27].
The C26 model for studies on cachexia and 
countermeasures
The C26 tumor enhances protein catabolism mediated by
muscle specific ubiquitin ligases, atrogin-1/MAFbx and
MuRF1 [28]. During muscle atrophy, thick, but not thin,
filament components are degraded by the ubiquitin-
dependent proteasome pathway [29], which is in agree-
ment with the finding that C26 burden induces specific
loss of myosin [30] and altered myosin isoform expres-
sion [31]. Thus, it has been suggested that muscle
cachexia results from highly selective targeting of protein
degradation [30]. In C26-bearing mice, the dystrophin
complex is downregulated, a phenomenon essential for
wasting, thereby highlighting a regulatory role of dystro-
phin in cachexia [28]. By exploiting the C26 model, we
demonstrated that Peg3/PW1 and p53 participate in a
positive feedback loop that regulates cachexia and stem
cell numbers in skeletal muscle [32]. We also noted that
cachectic muscles are enriched in stem cells with myo-
genic potential, though not in inflammatory cells [33].
Chemotherapeutic agents induce muscle wasting,
which consequently persists in spite of tumor remission
[34]. By contrast, indomethacin, ibuprofen and appetite
stimulants are among treatments shown to preserve mus-
cle mass in C26 tumor-bearing mice [35,36]. IL-6 medi-
ates muscle wasting induced by C26, even though it is not
the sole inducer of cachexia [37,38]. Indeed, it is theAulino et al. BMC Cancer 2010, 10:363
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milieu of circulating cytokines to determine the output in
terms of muscle wasting in C26-bearing mice, as indi-
cated by the finding that IL-27 treatment rescues muscle
wasting in these animals [25,37]. Myostatin negatively
regulates skeletal muscle mass, though inhibition of its
downstream pathways does not attenuate C26-induced
cachexia, thereby suggesting that myostatin does not play
a role in this context [39]. Anaerobic glycolysis in a C26
tumor is related to weight loss, while erythropoietin
a d m i n i s t r a t i o n  h a s  b e e n  s h o w n  t o  r e d u c e  w e i g h t  l o s s
[12]. Accordingly, exercise training attenuates C26-
induced muscle wasting [40]. High protein content, leu-
cine and fish oil reduce improves functional performance
in mice with cancer cachexia highlighting the relevance of
dietary supplementation for cachexia [41].
Given the clinical relevance of standardizing animal
models of cachexia, we performed a full characterization
of the C26-bearing mice, with the aim to provide a refer-
ence for further studies on an established model of cancer
which has been poorly described from the point of view
of cancer-associated cachexia. We pinpointed several
outputs, from organismal to molecular level, suitable for
the assessment of the progression of cancer and/or can-
cer-associated cachexia. Here we report for the first time
the rates of C26 tumor proliferation and apoptosis, a
detailed description of muscle wasting in relation to mus-
cle fiber type, ultrastructural features of the sarcomere in
cachexia underlying the novel, distinguishing functional
features of the wasting muscle, i.e. fatigue in the absence
of loss of specific force. These features characterize, on a
functional point of view, cancer cachexia from other
forms of muscle atrophy, such as sarcopenia, disuse or
dystrophy-associated atrophy.
Methods
Mice and tumor transplant
Cachexia was induced by subcutaneous grafting, using a
trocar, of a 0.5 mm3 fragment of colon carcinoma (C26,
obtained from the National Cancer Institute) in the dor-
sal region of 7-week-old BALB/c mice (Charles River,
Wilmington, MA). The tumor was either taken from a
frozen stock or dissected from a donor mouse within 30
min of the transplant. Tumors never went through more
than 15 passages in vivo (1 passage defined as growth
from transplant to 0.5-1 g). Animals were sacrificed 3 wks
following tumor implantation, unless otherwise specified.
Carcass weight was calculated as total body weight
devoid of tumor weight. Mice were treated in strict accor-
dance to the guidelines of the Institutional Animal Care
and Use Committee and to relevant national and Euro-
pean legislation, throughout the experiments.
Flow cytometric analysis
For bromodeoxyuridine (BrdU) experiments, the mice
received two injections of BrdU (50 mg/Kg body weight
each) 4 hrs apart on the day before analysis [42]. A 1:25
dilution of a monoclonal antibody against BrdU (clone
B44, BD, San Jose, CA) was used, followed by an
Alexa488-conjugated anti-mouse antibody (Molecular
Probes). DNA content was stained by incubation of the
cells with a PI/RNase solution (50 μg/ml and 100 U/ml)
for at least 3 hrs. Cell suspensions were analyzed with a
Coulter Epics XL flow cytometer (Beckman Coulter, Ful-
lerton, CA, USA). Gating strategy included eliminating
PI-negative debris and doublets based on DNA/peak
dimension ratio plotting. Samples incubated with an
aspecific murine primary antibody represented negative
controls. Data were analyzed with WinMDI 2.8 software
(a freeware developed by J. Trotter).
Tissue immuno-histochemical analyses
Extensor digitorum longus (EDL) muscles were dissected
with their tendons from each control and tumor-bearing
mouse, pooled and treated as described elsewhere [43].
Tumors or tibialis anterior muscles (TA) were frozen in
liquid nitrogen-cooled isopentane, sectioned and fixed
with 4% paraformaldehyde and stained with hematoxylin
(H) and eosin (E) (Sigma, St. Louis, MO) following stan-
dard procedures or, alternatively, immunostained with a
rabbit anti-laminin antibody (Sigma). Antibody binding
was visualized by using Alexa488-conjugated goat anti-
rabbit IgG (Molecular Probes) while nuclei were visual-
ized by Hoechst staining.
Apoptosis was assayed by TUNEL (Apoptag kit, Oncor,
Gaithersburg, MD), according to the supplier's instruc-
tions. Apoptotic and mitotic indexes were calculated on
H&E- stained sections by counting the number of mitotic
figures or TUNEL+ nuclei visible on high-power-field
40× objective in at least ten fields/sample and expressing
the results as percentage of the total number of cells in
the same fields.
NADH transferase staining was performed as
described previously [33]. Morphometric analysis was
performed on type IIb (low NADH transferase activity,
glycolytic) and type I (high NADH transferase activity,
oxidative) fibers separately, as described previously [44].
For each muscle, the whole muscle cross section was ana-
lyzed to calculate the average fiber size (cross-section
area) by using ImageJ 1.41 (freeware developed by Dr. W.
Rasband at NIH, and available at http://rsb.info.nih.gov/
ij). Photomicrographs were obtained by means of an
Axioskop 2 plus system (Zeiss, Oberkochen, GE) or a
Leica Leitz DMRB microscope fitted with a DFC300FX
camera (Leica, Wetzlar, Germany).Aulino et al. BMC Cancer 2010, 10:363
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RT-PCR and Western blot analysis
Total RNA was prepared from the TA muscle using Trizol
Reagent (Invitrogen, Carlsbad, CA), following the manu-
facturer's protocol. RT-PCR and Western Blot (WB) anal-
yses were performed using 2 μg of total reverse-
transcribed RNA and 80 μg of proteins [45]. WB mem-
branes were probed with a monoclonal antibody against
ubiquitin (clone P4G7-H11, Stressgen, Ann Arbor, MI).
Functional analysis
Functional analysis was performed according to a previ-
ously described protocol [45-47] on EDL and Soleus mus-
cles. The muscles were electrically stimulated by means
of a pair of electrodes, and evoked forces continuously
acquired. To evoke tetanic force (maximal force), muscles
were stimulated with two trains of 0.1 ms pulses (180 Hz
pulses for 0.4 s). Specific force was calculated by dividing
the tetanic force by the cross-sectional area of each mus-
cle [46]. Muscles were subjected to a further series of
closer trains of pulses (0.4 s train of 120 Hz pulses) to
induce isometric fatigue. During the fatigue stimulation,
we measured the ability of the muscle to resist to
repeated stimulations by calculating the time required to
halve the value of its own maximum force (fatigue time).
Results
C26 tumor histopathology
We subcutaneously implanted a solid fragment of about
0.5 mm3 of C26 colon carcinoma in the dorsal region of
mice. During the first week post-transplant, it was possi-
ble to locate the tumor by palpation. During the second
week post-transplant, it was possible to see the site of
tumor implant as a protrusion of the skin. During the
third week post-transplant, tumor growth was evident, it
being possible to see a mass underneath the skin; the
mass occasionally ulcerated, causing open wounds. When
surgically exposed, the C26 tumor was large, stiff and
roughly spherical in shape (Figure 1a). The tumor was
vascularized; it displayed a necrotic core when the diame-
ter significantly exceeded 1 cm, the mass in this case
weighing more than 1 g (data not shown).
The histological analysis revealed that the C26 is a par-
tially encapsulated, anaplastic carcinoma. The cells varied
in size, as did the nuclear/cytoplasm ratio. The degree of
vascularization was good for an ectopically-located
tumor, it being sufficient to sustain tumor growth and
survival. (Figure 1b). The mitotic and apoptotic indexes
(Figure 1c and 1d) were 5 ± 2% and 9 ± 3%, respectively.
Histochemical analysis showed the absence of inflamma-
tory infiltrate within the tumor mass. In particular CD3+
a n d  C D 8 +  l e u k o c y t e s ,  a s  w e l l  a s  m a c r o p h a g e s ,  w e r e
undetectable in, or immediately around, the tumor (data
not shown). Expression of Peg3, a growth-inhibitory
imprinted gene which is frequently down-regulated in
cancer, was absent (data not shown).
Characterization of C26 tumor growth
The tumor growth kinetics revealed a lag phase for the
first two weeks after transplant, followed by a growth
phase that gave rise to tumors larger than 2 g (Figure 2a).
We noted that growth kinetics gradually became slower
with the progression of the tumor passages in vivo (data
not shown). Three weeks following transplant, flow cyto-
metric analysis of PI-labeled tumor cells revealed the
presence of a significant sub-population of cells in the S
Figure 1 Morphological and histological features of C26 tumor. a) 
Exposed C26 tumor, three weeks following subcutaneous transplant of 
a 0.5 mm3 tumor fragment, has grown, becoming a spheroid measur-
ing 0.5-1 cm in diameter. The tumor mass is well-defined and vascular-
ized. Bar 5 mm. b) Photomicrographs of H&E-stained tumor 
cryosections. The tumor was collected three weeks following tumor 
transplant for histological analysis. Top, peripheral region showing tu-
mor encapsulation and, bottom, inner region showing anaplastic ap-
pearance and lack of a necrotic core. Inset, cell morphology and 
vascularization at higher magnification. Bar = 100 μm c) Mitoses (ar-
row) were evaluated on C26 tumor sections, based on cell morphology 
identified as typical of prophase to telophase, and expressed as per-
centage of the cells counted in 10 randomly chosen fields for each tu-
mor. An average mitotic index of 5 ± 2% (mean ± SEM) was calculated 
from data derived by four independent experiments (n = 8). d) TUNEL 
assay on C26 tumor sections of the same samples used for the mitotic 
index (the arrow points to a TUNEL+ cell) yielded an apoptotic index of 
9 ± 3% (mean ± SEM).Aulino et al. BMC Cancer 2010, 10:363
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Figure 2 C26 tumor proliferation. a) Tumor mass kinetics, measured upon tumor explant at the indicated times. After a lag time of about two weeks, 
tumor growth is linear and results in a mass of considerable size (>2 g, i.e. about 10% of the body weight). The mean ± SEM of at least three indepen-
dent experiments performed in triplicate is shown (for each data point, the number of replicates, "n", is: 9 < n < 22). b) The DNA profile by flow cytom-
etry of PI-labeled cells, at 3 weeks following transplantation, shows: a significant sub-population of cells in the S phase (M3), which indicates that tumor 
cells are actively proliferating; a haploid, sub-G1 peak (M1) that does not resemble apoptotic cells/debris; lack of polyploidism; M2 and M4 indicate 
the G1 and G2 sub-populations, respectively. c) BrdU incorporation (red) was detected in the tumor cells at 3 weeks following transplantation, the day 
after IP injections of two doses (50 mg/Kg of body weight) of BrdU 4 h apart (+ BrdU) though not in the sham-injected mice (-). Nuclei are counter-
stained with Hoechst (blue). Bar = 100 μm. Inset, confocal phase contrast image merged with the red fluorescence reveals the presence of BrdU+ and 
negative nuclei (black and white arrow, respectively). Bar = 10 μm d) Flow cytometric analysis of BrdU incorporation in cells enzymatically extracted 
from C26 tumors at 3 weeks following transplantation. BrdU+ cells were plotted against PI labeling (bottom) and compared to C26 cells from sham-
injected mice. Cells above background are in R2 and R3.Aulino et al. BMC Cancer 2010, 10:363
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phase (15 ± 1%); in addition, no polyploidism was found;
we instead noticed the presence of a hypodiploid peak
(Figure 2b). BrdU incorporation, corresponding to 9 ± 2%
of the cells by flow cytometric analysis (Figure 2d), was
detected in cell nuclei by immuno-fluorescence (Figure
2c). By plotting BrdU positive cells versus PI staining, we
noted several BrdU+ cells in the G1 phase, which indi-
cates that a significant fraction of the cell population pro-
ceeded through an entire cell cycle. Although we did not
systematically perform complete autopsies of the sacri-
ficed animals, we encountered only one case of metasta-
sis in the liver 50 days after tumor transplant, which
suggests a low metastatic potential.
Host systemic response to the C26 tumor
C26 tumor induced the death of 90% of the mice within
32 days from the transplant, with an average survival time
of 25 days (data not shown). The hallmark of the host
response to tumor load was cachexia (Figure 3a). Tumor-
bearing mice appeared emaciated and had disheveled fur
(Figure 3a). Body weight loss was unaffected in the first
two weeks following tumor transplant, but was cata-
strophic in the third week, when tumor-bearing mice
reached a 30% weight loss plateau (Figure 3b). Body
weight loss was largely accounted for by muscle wasting
(as shown in Figure 3c) accompanied by disappearance of
fat pads (Figure 3d). Although we did not perform a sys-
tematic analysis, we observed that numerous skeletal
m u s c l e s  t h r o u g h o u t  t h e  bod y  w e r e  a f f e c t ed  b y  m u s c l e
wasting, as shown by decreased muscle mass (Table 1).
Two-way ANOVA demonstrated a significant effect on
muscle mass induced by the presence of the tumor (i.e.
bona fide cancer-induced muscle wasting). ANOVA indi-
cated also no interaction between the two variables, i.e.
muscle type and presence of the tumor, in affecting mus-
cle mass. In fact, the muscles we analyzed displayed a
similar degree of wasting, regardless of their intrinsic dif-
ferences in fiber number and physiological properties
(Table 1). Skeletal muscle and fat tissue appeared to be
affected most by the presence of C26 tumor, there being
several organs that did not waste to a similar degree (Fig-
ure 3e). We noted splenomegaly, characterized by a sig-
nificant, 3-fold increase in the spleen weight of tumor-
bearing mice (Figure 3d).
C26 tumor-induced muscle fiber atrophy
While muscle fibers being the bulk element of the muscu-
lature, whole muscle mass is affected by several tissues,
which are intermingled with skeletal muscle fibers. In
evaluating muscle wasting it is therefore important to
assess muscle fiber specific events. Thus, we analyzed the
muscle fiber specific response to tumor burden by a com-
bination of immunohistochemical and morphometric
approaches. The lysosomal proteolytic system is stimu-
lated in adult muscles in a variety of pathological condi-
tions; lysosome accumulation in the fibers was not,
h o w e v e r ,  o b s e r v e d  i n  c a n c e r  c a c h e x i a  b y  a s p e c i f i c
esterase staining (Figure 4a); nonetheless, we did note
that tumor load induced marked muscle fiber atrophy. To
quantify this phenomenon, we performed a morphomet-
ric evaluation of a muscle fiber cross-sectional area on
subpopulations of fibers with different biochemical prop-
erties, based on NADH-transferase. The latter identifies
oxidative, glycolytic and intermediate fibers according to
their mitochondrial content and oxidative capacity (Fig-
ure 4b). We found that the C26 tumor induced a shift in
both glycolytic and oxidative fibers toward smaller cross-
sectional areas (Figure 4b). Accordingly, muscle fiber
atrophy was apparent when we performed immunostain-
ing for laminin, an important component of the extracel-
lular matrix (i.e. the basement membrane) that
individually surrounds the fibers (Figure 4c). We noted
that laminin staining was blurred in muscles from tumor-
bearing mice, suggesting the occurrence of basement
membrane disorganization (Figure 4c). The enzymatic
isolation of single fibers from the musculature of mice is
an approach commonly used to study muscle fibers sur-
rounded by their basement membrane. We applied this
approach to cachectic muscles; the observation of
Table 1: C26 induces muscle wasting
TREATMENT MUSCLE
Soleus EDL Tibialis
Control (weight, g) 6.3 ± 0.2 12.5 ± 0.4 42.7 ± 2.4
C26 (weight, g) 4.9 ± 0.1 * 9.7 ± 0.3 * 30.5 ± 0.9 *
C26 (weight, % of control) 77% 77% 71%
The indicated muscles were dissected from control or tumor-bearing (C26) mice three weeks following tumor transplant and their wet mass 
evaluated. Reported is the mean ± SEM of at least three independent experiments (for each data point, the number of replicates, "n", is: 4 < 
n < 10). Two-way ANOVA (F = 92.3, p < 0.0001 between rows; F = 534.9, p < 0.0001 between columns) indicates a statistically significant effect 
on muscle mass, independently of muscle type, induced by the presence of the tumor. * = p < 0.01 versus matching control by Student's t test.Aulino et al. BMC Cancer 2010, 10:363
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Figure 3 C26-induced cachexia. a) Gross appearance of control (left) compared with tumor-bearing mice (right) at 3 weeks following tumor implant. 
b) Carcass weight loss, defined as the total weight minus the tumor weight at given time points and reported as a percentage of the initial weight of 
each mouse. Non-significant weight loss is observed for up to two weeks of tumor burden, followed by 30% weight loss in the third week. c) If com-
pared with a healthy mouse (left), the hindlimb of a tumor-bearing mouse (right) is severely atrophied at 3 weeks following transplantation. d) Dorsal 
and abdominal view of subcutaneous fat pads in control (left panels, arrows) and C26-bearing mice (right panels) at 3 weeks following transplantation. 
The subcutaneous fat is virtually absent in cachexia. e) The weight of several internal organs is unaffected 3 weeks following tumor transplant, while 
the spleen is hypertrophic. p > 0.01 by Student's t test if compared with the weight of matching organs from control animals. The mean ± SEM of two 
experiments performed in triplicate is shown.Aulino et al. BMC Cancer 2010, 10:363
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Figure 4 Muscle fiber atrophy in C26-bearing mice. a) Esterase staining of TA cross-sections from control (left) and tumor-bearing (right) mice, 
three weeks following transplant. Fiber atrophy is evident in different fiber types in the absence of lysosome accumulation. The intensely stained neu-
romuscular junctions are also visible. Bar = 50 μm. b) NADH-transferase staining can be used to differentially analyze larger, glycolytic fibers (arrow) 
and smaller, oxidative fibers (arrowhead), in TA cross-sections from control (top) and tumor-bearing (bottom) mice. Intermediate fibers are also visible. 
The fiber cross-sectional area (CSA) was measured, and the distribution is shown for both glycolytic and slow fibers, in control (black bars) and C26-
bearing (gray bars) mice. The average size ± SEM of each fiber size class calculated from replicate experiments is shown, along with the medians of 
each distribution. C26-induced fiber atrophy is detectable in both fiber types. c) Immunostaining for laminin (green) on TA cross-sections from control 
(left) and tumor-bearing (right) mice, three weeks following transplant, showing alterations in the basement membrane. Bar = 100 μm. d) Immunos-
taining for laminin (red) performed on enzymatically isolated fibers, obtained from EDL of control (left) and tumor-bearing (right) mice, and longitudi-
nally depicted by confocal microscopy. Nuclei are counterstained with TO-PRO and pseudo-colored in blue. Bar = 30 μm.Aulino et al. BMC Cancer 2010, 10:363
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remarkable fiber shrinkage in cachexia confirmed our
previous findings (Figure 4d).
Ultrastructural alterations of myofilaments in tumor-
bearing mice
Studies have shown that the myofilament protein content
in atrophic muscles is reduced and the sarcomere align-
ment altered, as seen in longitudinal sections. W e thus
investigated the sarcomeric architecture in ultrathin
cross-sections from control and tumor-bearing mice. At
the level of the A-band, normal sarcomeres appeared full
of both thick and thin filaments, the latter in the typical
hexagonal formation surrounding each myosin filament
( F i g u r e  5 a ) .  W e  f o u n d  t h a t  m o s t  o f  t h e  s a r c o m e r e s  i n
cachectic muscle were disrupted, that both types of fila-
ment were poorly defined, and that while the cisternae of
the sarcoplasmic reticulum were still present, the sarco-
meric perimeter was less clearly delimited (Figure 5b).
Muscle wasting associated with increased protein 
degradation and loss of function
As proteins are the main components of bulk muscle
mass, we investigated protein degradation in the muscu-
lature upon tumor burden. We noted a significant up-reg-
ulation of muscle specific E3 ubiquitin ligase Atrogin-1
expression in tumor-bearing mice, suggesting the
involvement of proteasome-mediated protein degrada-
tion in cachectic muscles (Figure 6a). WB analysis of
muscle extracts revealed that protein ubiquitination was
qualitatively and quantitatively affected by C26 tumor
(Figure 6b). These results indicate a general upregulation
of protein degradation phenomena induced by tumor
burden.
Muscle fiber atrophy and dismantling of sarcomeric
proteins typically lead to impaired muscle performance.
We evaluated muscle force and fatigue of EDL and Soleus
muscles in control and tumor-bearing mice and found
that cachectic muscle displays a lower maximal force than
control muscle (data not shown), which confirms previ-
ous findings. C26 tumor did not affect the specific force,
i.e. normalized by muscle size, of either muscle, but it sig-
nificantly reduced the fatigue time of the EDL, thereby
indicating that C26 negatively affects muscle function,
mostly by diminishing resistance to fatigue (Figure 6c).
When we investigated the fatigue time of the Soleus mus-
cle, which has a different fiber composition from the
EDL, being enriched in type I fibers, we did not notice a
significant decline in muscle performance upon tumor-
burden. These findings highlight heterogeneity in the
functional performance of different muscles in response
to tumor-burden.
Discussion
In 2002, there were approximately one million new cases
of colon cancer worldwide, making it one of the leading
causes of cancer death; moreover, its prevalence was
increasing in some countries [48]. The clinical relevance
of colon cancer led to an unparalleled experimental use of
animal models. Mice bearing the C26 colon carcinoma
represent an established murine model of cancer [8,9].
Cachexia is associated with most cancers, including the
murine C26 colon carcinoma [10]. Consequently, there is
a striking discrepancy between the 188 papers yielded by
the query "C26 AND cancer" and the 8 papers yielded by
the query "C26 AND cachexia" in the NCBI's PubMed
system, the most widely used method for accessing MED-
LINE. Noticeably, the search using "C26 AND cancer"
Figure 5 Ultrastructural characterization of sarcomeres in ultra-
thin cross-sections of TA from control (top) and tumor-bearing 
(bottom) mice observed by transmission EM. A disarrangement of 
the myofilament hexagonal organization at the level of the A-band is 
observed upon tumor burden. Bar = 250 nm.Aulino et al. BMC Cancer 2010, 10:363
http://www.biomedcentral.com/1471-2407/10/363
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Figure 6 Protein ubiquitination and fatigue induced by C26. RT-PCR (a) and WB (b) analyses show the upregulation of E3 ligase (Atrogin-1)-me-
diated protein ubiquitination in the TA of tumor-bearing mice (C26). GAPDH is shown as loading control. c) The functional analysis of the EDL from 
control (open bar) and C26-bearing (solid bar) mice shows unaltered specific force (i.e. tetanic force normalized by muscle mass) and reduced fatigue 
time (i.e. time required to halve titanic force upon repeated stimuli) in cachectic muscles. p > 0.05 by Student's t test. The mean ± SEM of two exper-
iments performed in triplicate is shown.Aulino et al. BMC Cancer 2010, 10:363
http://www.biomedcentral.com/1471-2407/10/363
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does not retrieve very important works on cancer
cachexia that exploited the C26 model [28,32]. PubMed
employs a Boolean search strategy, which suffers, among
other shortcomings, from differences in term usage
between searchers and indexers [49]. It is apparent that
the communities of scientists exploiting the C26 model to
study either cancer or cachexia are not aware of each
other's works, and this may have deleterious conse-
quences for the progress of integrative medicine applied
to a complex syndrome associated with underlying ill-
ness. We suggest that "C26" be included among the key-
words whenever work is conducted on this experimental
model to provide adequate visibility.
The definition of the C26 tumor as adenocarcinoma is a
major mistake in terminology [10,12,35]. We have con-
firmed that the C26 cells, originally obtained from a
colon carcinoma, when ectopically implanted in mice
form an undifferentiated carcinoma, which should thus
be referred to as such. This tumor has a growth rate com-
parable to that of other carcinomas in rodents [50], with
the mass growing to a significant size that corresponds to
10% of the body weight at 40 days. Such a large tumor
mass is inconceivable in the clinical setting. However, it is
worth noting that we observe a significant effect on both
body weight loss (this work) and muscle fiber atrophy
[33] far before the tumor reaches such a significant size.
In particular, we note that during the lag phase of tumor
growth, i.e. within the first two weeks following tumor
transplantation, the presence of the tumor already affects
fiber size [33]. At day 16 (i.e. at the onset of tumor mas-
sive growth) body weight loss is already significant and
has reached a plateau. While body weight negatively cor-
relates with tumor mass in some animal models, such as
the MAC-16 -bearing mice [51], this correlation is not
straightforward and depends on the type of tumor. Lung
carcinoma-bearing mice do not loose weight during
tumor growth while sarcoma-bearing mice loose more
than 10% of their initial weight in the same time frame
[52]. This is in agreement with an independent report
showing that sarcoma-bearing rats display a catastrophic
weight loss at 14 days following tumor transplant, when
the latter has not significantly grown yet [53]. The fact the
maximal weight loss precedes the maximal tumor growth
is a useful feature since cachexia may thus be observed in
the absence of significant disturbing factors, such as a rel-
evant tumor mass. This phenomenon also indicates a non
linear relation between tumor size and cachectic effects,
highlighting the complexity of the underlying mecha-
nisms. We observed relatively low standard deviations
associated to any given data point of the tumor growth
kinetics, even during the time lapse corresponding to the
fastest tumor growth, which mirrors a good reproducibil-
ity of the experimental procedure. We inject a solid frag-
ment (of standard dimensions) of the tumor rather than a
cell suspension. We speculate that, with our approach, all
the tumor cells remain in place and are exposed to the
same niche, thus leading to a highly reproducible output.
This is a very important issue, given the relevance of stan-
dardization in animal models of cancer-cachexia.
In keeping with tumor cell DNA distribution, C26 cells
are not polyploid, but display a hypodiploid peak that is
not accounted for by apoptosis. Carcinomas have been
reported to be associated with hypodiploid cells, whose
presence may represent a poor prognosis factor [54,55].
The growth-inhibitory imprinted gene Peg3 is not
expressed by C26 cells, which is highly relevant since loss
of Peg3 expression through promoter methylation, loss of
heterozygosity and other mechanisms may stimulate clo-
nogenic growth and contribute to the pathogenesis of a
number of cancers [56,57]. The results regarding the met-
astatic potential of C26 are controversial [8,9]. In our
studies, the low incidence of metastases and the time
required for them to occur are in agreement with Sato et
al.'s work and suggest that the C26 model may be
exploited for studies on metastases-free tumors.
We found that the host response to C26 tumor burden
includes splenomegaly, another controversial result [8-
10]. Splenomegaly is a marker of tumor progression that
is associated with leukemoid reaction [58,59]. Few studies
have addressed the interactions between inflammatory
cells and skeletal muscle in cachexia. We found that the
number of leukocytes, neutrophils and macrophages
does not increase, but may on the contrary be depleted in
the endomysium of tumor-bearing mice [33]. We thus
b e l i e v e  t h a t  t h e  m u s c l e  d a m a g e  o b s e r v e d  i n  c a n c e r
cachexia [28] is not attributable to leukocytes, neutro-
phils and macrophages, even though inflammatory cells
do induce muscle damage and regeneration in different
contexts [60]. On the contrary, the partial cancer-associ-
ated immuno-depression displayed by C26-tumor bear-
i n g  m i c e  m a y  be  r e l eva n t  t o  ca c h e x i a,  s i n c e  a  r o l e  f o r
immune cells in protection from cachexia has been
reported in a different experimental setting [61]. These
findings are in agreement with the evidence that treat-
ments leading to an improved immune competence are
beneficial against cancer cachexia [62].
The hallmark of the host response to tumor burden is
cachexia [10]. Wasting is a direct effect of circulating
cytokines on skeletal muscle metabolism and cannot be
ascribed to cancer-associated anorexia, since food intake
by C26-bearing mice is not significantly different from
that of controls [28]. Nonetheless, we and others
observed a significant loss of both fat and lean mass
induced by the presence of a tumor. We observed that
muscle wasting is associated to increased protein degra-
dation, as shown by increased protein ubiquitination in
muscles from C26-bearing mice. Cachexia, sarcopenia,
and disuse atrophy are wasting conditions characterizedAulino et al. BMC Cancer 2010, 10:363
http://www.biomedcentral.com/1471-2407/10/363
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by loss of muscle mass. These conditions result in differ-
ent metabolic adaptations: increased rate of protein deg-
radation in cachexia, as opposed to unchanged protein
degradation in inactivity or sarcopenia [63]. The loss of
both adipose and muscle tissue is a specific feature of
cachexia, making it possible to further distinguish
cachexia from sarcopenia, which is characterized by loss
of lean but not fat mass. Taken together, these features
allow a clear discrimination among different wasting con-
ditions and indicate that cachexia is distinct from sar-
copenia and from disuse. Accordingly, this concept has
been included in the recently released consensus defini-
tion of cachexia [7].
Since loss of muscle mass is a hallmark of muscle wast-
ing, we have measured the mass of several muscles,
namely the Soleus, the EDL and the Tibialis. These mus-
cles differ insomuch as they have very different sizes and
functions, while being all anatomically located in the dis-
tal extremity of the lower limbs. Differential functions are
mirrored by a different fiber type composition and oxida-
tive metabolism, with the Soleus and EDL being predomi-
nantly composed of slow (oxidative) and fast (glycolytic)
fibers, respectively; the Tibialis has a mixed fiber popula-
tion. We showed that all the muscle analyzed were
severely cachectic. Two-way ANOVA demonstrated that
the C26 tumor significantly affects the muscle mass irre-
spectively of its initial size and type. We therefore con-
clude that muscle wasting appears to be a generalized
response to tumor-burden, even though we cannot
exclude that some muscles are spared (which would be
demonstrated only by a systematic analysis on virtually
the entire musculature). This is a novel, relevant finding;
however, it does not imply that all muscles are equal with
regard to all responses: for instance, both Soleus and EDL
become cachectic in the presence of the C26-tumor but
they do not have superimposable functional deficits (dis-
cussed below).
Muscle wasting is due to muscle fiber atrophy. The
decline in muscle mass observed in both Soleus and EDL
in spite of the differences in fiber type composition sug-
gested that fiber atrophy is not fiber-type dependent. To
directly address this issue, we measured muscle fiber CSA
in two different fiber populations (oxidative and glyco-
lytic fibers identified by NADH-transferase staining) in
the same muscle, namely the EDL. We observed atrophy
of both glycolytic and oxidative fibers, the latter previ-
ously reported to be resistant to cachexia [28], an obser-
vation based on the assessment of fiber diameter rather
than on that of fiber cross-sectional area, as ours instead
was. The latter method may be more sensitive to minor
changes that would otherwise escape detection. Our find-
ings that the tumor induces a significant decrease of the
Soleus muscle mass and of the oxidative fibers in the EDL
indicate that, irrespectively of muscle type, the C26
tumor does affect a fiber type generally considered "more
resistant" to cachexia.
Proteasome-mediated degradation of ubiquitinated
proteins leads to sarcomere dismantling [29]. Therefore,
we investigated the structure of the sarcomeres in cross-
section at the ultrastructural level. We showed that in
cachexia disorganization occurs of the otherwise highly
organized array of actin and myosin myofilaments. While
the selective targeting of myosin heavy chain for degrada-
tion in cancer cachexia was recently reported [30], this is
the first direct demonstration of a deficit in the contrac-
tile system of cachectic muscles. In addition to protease-
and proteasome-mediated digestion, autophagy plays a
significant role in muscle fiber atrophy [64], though we
did not notice an increase in the number of lysosomes in
cachectic muscle fibers by staining for esterase activity.
This does not formally exclude a relevant role of
autophagy in C26-induced muscle wasting and this issue
needs further investigation. Alterations in the dystrophin
complex that anchors muscle fibers to the basement
membrane have been reported to occur in C26-induced
cachexia [28]; this may explain the blurred appearance of
laminin, one of the main components of the basement
membrane. In fact, cachectic fibers show an irregular sur-
face and a general deregulation of the cell-matrix interac-
tions  in vivo [28]. Dystrophinopathies in colorectal
cancer patients have also been reported [28] (Zampieri S.
et al., 2010 Spring Padua Muscle days, Terme Euganee,
Padua, Italy, april 22-24, 2010: p. 69; in press; online on
http://www.bio.unipd.it/bam/). These acquired myopa-
thies are the earliest muscle markers of cachexia observed
to date, since they occur before the onset of cancer-asso-
ciated cachexia [65,66]. For all the above, we think that it
is very important to assess the status of the sarcolemmal
proteins, and/or of the proteins of the basement mem-
brane connected to the sarcolemma, in a cancer cachexia
study and that this should be a routine procedure. We
have shown that both p53 and Peg3/PW1 are expressed
in the musculature and mediate muscle atrophy [32].
These two factors are also regulators of myogenic differ-
entiation in vitro and muscle regeneration in response to
cytokines [13,32,44,45,67]. Since dystrophin downregula-
tion renders cachectic muscle particularly fragile [28], a
reduced regenerative capacity may cause muscle wasting.
From a clinical point of view, muscle weakness and
fatigue are among the leading causes of distress in
cachexia. Although maximal tetanic force is reduced by
C26 [68], this reduction is not substantial when force is
normalized by a muscle mass index, yielding the so-called
specific force. This suggests that the drop in maximal
force is merely due to muscle wasting and not to altera-
tions in the intrinsic contractile properties of the myofi-
bers. We have shown that the EDL muscle has a 25%
decrease in the fatigue time as compared to the healthyAulino et al. BMC Cancer 2010, 10:363
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control. Thus, we propose that muscle fatigability, rather
than muscle force, is a hallmark of cachectic muscle func-
tional deficit. Interestingly, the Soleus muscle showed a
smaller, non significant decline in the fatigue time, indi-
cating that resistance of this muscle is spared in cachexia.
This occurs in spite of the fact that the Soleus is atrophic
in cachexia. This phenomenon highlights the heterogene-
ity of the muscle responses to cancer and the importance
of addressing multiple parameters for different muscles
to fully characterize cachexia in vivo.
Conclusions
The current consensus definition for cachexia - "[...] a
complex metabolic syndrome associated with underlying
illness and characterized by loss of muscle with or with-
out loss of fat mass [...]" [7]- translates into the following
diagnostic criteria: weight loss of at least 5% in 12 months
in the presence of illness, and at least three of the follow-
ing features: decreased muscle strength; fatigue; anorexia;
low fat-free mass index; abnormal biochemistry (e.g.
inflammatory/protein degradation markers). While this
definition has not been tested in epidemiological or clini-
cal studies, a consensus operational definition provides
an opportunity for increased research. C26 carcinoma-
bearing mice display all these features with the exception
of anorexia, with the caveat that a more severe (about
20%) weight loss is to be expected in mice, compared to
humans. We conclude that the C26 carcinoma ectopically
implanted into BALB/c mice represents a good experi-
mental model for research on both cachexia and underly-
ing cancer. Our work also pinpoints several biochemical,
cellular and physiological outputs that can be used in a
standardized manner to assess muscle wasting and the
underlying tumor growth in studies aimed to demon-
strate the effects of pharmacological or genetic interven-
tions against cancer cachexia.
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